PathAI

#ICYMI Andrew Beck, MD, PhD, co-founder and CEO of PathAI, sat down with Dermatology Times to discuss the future of #AI in #dermatopathology research. He shared insights on how AI is revolutionizing dermatopathology research by improving accuracy and enhancing workflow efficiency, with the future vision of helping #dermatologists and #pathologists deliver faster, more precise care to patients.   🌐 At PathAI, we’re committed to advancing AI-driven #pathology to unlock new possibilities in dermatology and beyond. 🖥️ 🖱️ Check out the interview here to learn more: https://lnkd.in/gQCX5JPT

🌐 That’s a wrap on #ECCO2025 in Berlin, Germany! Senior Biomedical Data Scientist John Shamshoian presented "𝘘𝘶𝘢𝘯𝘵𝘪𝘵𝘢𝘵𝘪𝘷𝘦 𝘏𝘪𝘴𝘵𝘰𝘭𝘰𝘨𝘪𝘤 𝘍𝘦𝘢𝘵𝘶𝘳𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘐𝘯𝘧𝘭𝘢𝘮𝘮𝘢𝘵𝘰𝘳𝘺 𝘔𝘪𝘤𝘳𝘰𝘦𝘯𝘷𝘪𝘳𝘰𝘯𝘮𝘦𝘯𝘵 𝘜𝘴𝘪𝘯𝘨 𝘋𝘪𝘨𝘪𝘵𝘢𝘭 𝘗𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺 𝘗𝘳𝘪𝘰𝘳 𝘵𝘰 𝘈𝘥𝘢𝘭𝘪𝘮𝘶𝘮𝘢𝘣 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘈𝘭𝘭𝘰𝘸𝘴 𝘗𝘳𝘦𝘥𝘪𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘙𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘪𝘯 𝘗𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘜𝘭𝘤𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘊𝘰𝘭𝘪𝘵𝘪𝘴" highlighting how our #digitalpathology and #machinelearning studies with our #biopharma partners have the potential to predict treatment responses for #UlcerativeColitis clinical research, paving the way for a #precisionmedicine approach in #IBD #AI #Pathology #Histopathology #Biopharma

📅 On Friday, February 21, 2025, at 9:10 AM CET, John Shamshoian PhD, Senior Biomedical Data Scientist at PathAI, will present at Session 7: Clinical Trials IV during #ECCO2025 in Berlin, Germany! 🇩🇪 The presentation, titled "𝘘𝘶𝘢𝘯𝘵𝘪𝘵𝘢𝘵𝘪𝘷𝘦 𝘏𝘪𝘴𝘵𝘰𝘭𝘰𝘨𝘪𝘤 𝘍𝘦𝘢𝘵𝘶𝘳𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘐𝘯𝘧𝘭𝘢𝘮𝘮𝘢𝘵𝘰𝘳𝘺 𝘔𝘪𝘤𝘳𝘰𝘦𝘯𝘷𝘪𝘳𝘰𝘯𝘮𝘦𝘯𝘵 𝘜𝘴𝘪𝘯𝘨 𝘋𝘪𝘨𝘪𝘵𝘢𝘭 𝘗𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺 𝘗𝘳𝘪𝘰𝘳 𝘵𝘰 𝘈𝘥𝘢𝘭𝘪𝘮𝘶𝘮𝘢𝘣 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘈𝘭𝘭𝘰𝘸𝘴 𝘗𝘳𝘦𝘥𝘪𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘙𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘪𝘯 𝘗𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘜𝘭𝘤𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘊𝘰𝘭𝘪𝘵𝘪𝘴", will showcase how our #digitalpathology and #machinelearning studies with our partners have the potential to predict treatment responses for #UlcerativeColitis clinical research, paving the way for a #precisionmedicine approach in #IBD. 📝 Read the abstract published in Journal of Crohn's and Colitis last month: https://lnkd.in/e-zYS2qN We’re excited to share our findings and push the boundaries of what’s possible in digital pathology! #ECCO2025 #Pathology #AIPathology #AI #PrecisionMedicine #ClinicalTrials

🏆 Our annual Pathy Awards are all about recognizing and celebrating our team members who embody PathAI I values in everything they do:  𝘗𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘍𝘪𝘳𝘴𝘵, 𝘈𝘤𝘤𝘰𝘶𝘯𝘵𝘢𝘣𝘪𝘭𝘪𝘵𝘺, 𝘛𝘦𝘢𝘮, 𝘏𝘶𝘮𝘪𝘭𝘪𝘵𝘺 & 𝘈𝘭𝘭 𝘐𝘯. This award not only recognizes incredible work happening across PathAI, but it celebrates how the work is done—through a relentless focus on bringing out the best in one another. This year, amidst dozens of nominations and after a rigorous selection process, our leadership team selected one standout team member, Lily Windholz, a Program Manager on our PMO team, whose commitment to excellence, strong work ethic, and dedication to patient impact is well known at PathAI. We are excited to honor her contributions and above-and-beyond effort in 2024! Join our team & mission today: https://lnkd.in/e8GArtha #Pathology #AIPathology #AI #Hiring #OpenPositions #healthtech #biotech

Love is in the air and in the lab! 💌 Happy Valentine’s Day from PathAI. Here’s to collaborations, partnerships, and connections that spark passion and discovery ❤️ #HappyValentinesDay #Pathology #DigitalPathology #AI

👩🔬 This year is the 10th anniversary of the International Day of Women and Girls in Science (#IDWGS), a celebration #diversity in #STEM fields and a call to action for continued progress. In honor of #IDWGS2025, we’re highlighting insights from five women in science working at PathAI in a variety of ways. We asked them what inspired them to get into science, what they love about the field, and their hopes for their scientific work at PathAI—read on to hear more in their own words. Featuring Christina Jayson, Ph.D., Ylaine Gerardin, Jacqueline Brosnan-Cashman, Ph.D., Abigail Emerson, and Shima Nofallah #WomenInSTEM

🇧🇷 We're thrilled to announce a strategic partnership with Rede D'Or São Luiz, the largest health system in Brazil, to bring AI-powered #digitalpathology solutions to South America 📝 Read the Press Release: https://lnkd.in/esTdVgJG Rede D’Or will implement PathAI’s AISight® Image Management System across its #pathology operations which support the national network of 78 #hospitals. The platform integrates advanced AI algorithms, including PathAI’s AIM-Breast Biomarker panel supporting ER, PR, HER2, and Ki67 quantification, to support #pathologyworkflows. Rede D’Or will also utilize PathAI’s tools for research purposes. 💬 “This partnership demonstrates how leading healthcare institutions can successfully integrate digital and computational solutions to improve operational efficiency and advance research capabilities to deepen our understanding of diseases and refine treatment approaches,” said Andrew Beck, MD, PhD, co-founder and CEO of PathAI. “Rede D’Or’s commitment to innovation in healthcare as a means to improve patient outcomes makes them the ideal partner for introducing our technology to the Latin American market.” #healthtech #biotech #partnership .......... AIM-IHC Breast Panel is for Research Use Only, not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.

🌐 PathAI scientists and partners have recently published “Impact of a #machinelearning-powered algorithm on pathologist #HER2 #IHC scoring in #breastcancer” in medRxiv. 📝 Read the publication: https://lnkd.in/gwj454RX #Biomarker assessment is essential for #clinicaltrial enrollment and endpoint assessment as well as for optimal treatment determination in patients with #breastcancer. While manual pathologist scoring remains the standard for predicting HER2 #immunohistochemistry (IHC) status, there is an opportunity to improve inter-pathologist consistency for HER2 scoring. In this paper, we detail the development of an #AIPathology tool, designed to assist researchers by providing interpretable scores of HER2 IHC, consistent with ASCO/CAP guidelines, using digitized whole slide images. Use of this model as an “AI-assist” tool improved inter-pathologist agreement and positive percent agreement overall and at the 0/1+ and 1+/2+ scoring cutoffs. We also show that when interacting with this tool, pathologists overrode the model’s suggestion at varying rates, with the quality of a pathologist’s overrides being correlated with their manual accuracy. #AI #digitalpathology #Pathology

Want to learn more about our new PathAssist Derm tool for #dermatopathology research? We sat down with Santhosh Balasubramanian, Director of #AI Products at PathAI, to discuss: 🔬 The unique challenges in #dermatology & skin #cancer research 🔍 Why PathAI made the move into dermatopathology  🔑 Key features of PathAssist Derm for researchers 🌐 The ways AI is poised to help dermatopathology researchers  and benefit the field 💬 Read our full Q&A with Santhosh and let us know what you think in the comments about dermatopathology and the state of the field today. - Learn more about PathAssist Derm: https://lnkd.in/eB3M5tZZ - Reach out to us for a free demo: [email protected] ........ #AIPathology #Biotech #HealthTech #Pathology #DigitalPathology #SkinCancer #Cancer PathAssist Derm is for research use only. Not for use in diagnostic procedures.

🖥️ 🖱️ Meet your new #AI #dermatopathology research assistant: PathAssist Derm. Now available on the AISight® Image Management System, designed to streamline your #skincancer research and #digitalpathology workflows. 💡 Learn more: https://lnkd.in/eB3M5tZZ 🗓️ Schedule a demo today: https://lnkd.in/eSiWeaaf This advanced tool is purpose-built to assist researchers with precise, scalable, and efficient dermatopathology workflows, focusing on: ✔️ Automated Orientation: Quickly aligns tissue sections, eliminating the manual slide adjustments traditionally required. ✔️ AI Classification: Differentiates melanocytic, basaloid, and squamous lesions, including subtypes such as melanoma in situ (MIS), invasive #melanoma, and squamous cell carcinoma. ✔️ Quantitative Analysis: Provides calibrated measurements of the lesion, ensuring data consistency across large-scale studies. ✔️ Ancillary Testing Recommendations: Guides researchers with relevant ancillary stains tailored to specific lesion types. 🔎 PathAssist Derm is multi-scanner compatible and supports high-throughput H&E analysis, enabling researchers to sort and prioritize worklists based on AI-predicted lesion classifications. This capability significantly reduces manual assessments, speeds up research workflows, and helps uncover actionable insights in #skincancer research. #Biotech #AIpathology #cancer #cancerresearch #USCAP ................... PathAssist Derm for research use only. Not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.